RESUMEN
The Rho GTPase family proteins are key regulators of cytoskeletal dynamics. Deregulated activity of Rho GTPases is associated with cancers and neurodegenerative diseases, and their potential as drug targets has long been recognized. Using an economically effective drug screening workflow in fission yeast and human cells, we have identified a Rho GTPase inhibitor, O1. By a suppressor mutant screen in fission yeast, we find a point mutation in the rho1 gene that confers resistance to O1. Consistent with the idea that O1 is the direct inhibitor of Rho1, O1 reduced the cellular amount of activated, GTP-bound Rho1 in wild-type cells, but not in the O1-resistant mutant cells, in which the evolutionarily conserved Ala62 residue is mutated to Thr. Similarly, O1 inhibits activity of the human orthologue RhoA GTPase in tissue culture cells. Our studies illustrate the power of yeast phenotypic screens in the identification and characterization of drugs relevant to human cells and have identified a novel GTPase inhibitor for fission yeast and human cells.
Asunto(s)
Proteínas de Unión al GTP Monoméricas , Schizosaccharomyces , Proteína de Unión al GTP rhoA , Humanos , Citoesqueleto , Evaluación Preclínica de Medicamentos , Proteínas de Unión al GTP Monoméricas/antagonistas & inhibidores , Proteína de Unión al GTP rhoA/antagonistas & inhibidores , Schizosaccharomyces/enzimologíaRESUMEN
The RAS superfamily of small GTPases regulates major physiological cellular processes. Mutation or deregulation of these small GTPases, their regulators and/or their effectors are associated with many diseases including cancer. Hence, targeting these classes of proteins is an important therapeutic strategy in cancer. This has been recently achieved with the approval of the first KRASG12C covalent inhibitors for the clinic. However, many other mutants and small GTPases are still considered as 'undruggable' with small molecule inhibitors because of a lack of well-defined pocket(s) at their surface. Therefore, alternative therapeutic strategies have been developed to target these proteins. In this review, we discuss the use of intracellular antibodies and derivatives - reagents that bind their antigen inside the cells - for the discovery of novel inhibitory mechanisms, targetable features and therapeutic strategies to inhibit small GTPases and their downstream pathways. These reagents are also versatile tools used to better understand the biological mechanisms regulated by small GTPases and to accelerate the drug discovery process.
Asunto(s)
Anticuerpos/metabolismo , Proteínas de Repetición de Anquirina Diseñadas/metabolismo , Descubrimiento de Drogas/métodos , Proteínas de Unión al GTP Monoméricas/metabolismo , Neoplasias/enzimología , Transducción de Señal/efectos de los fármacos , Anticuerpos de Dominio Único/metabolismo , Animales , Anticuerpos/inmunología , Anticuerpos/farmacología , Proteínas de Repetición de Anquirina Diseñadas/farmacología , Humanos , Terapia Molecular Dirigida/métodos , Proteínas de Unión al GTP Monoméricas/antagonistas & inhibidores , Proteínas de Unión al GTP Monoméricas/inmunología , Neoplasias/tratamiento farmacológico , Unión Proteica , Proteolisis/efectos de los fármacos , Anticuerpos de Dominio Único/inmunología , Anticuerpos de Dominio Único/farmacologíaRESUMEN
The Ras superfamily of small GTPases are guanine-nucleotide-dependent switches essential for numerous cellular processes. Mutations or dysregulation of these proteins are associated with many diseases, but unsuccessful attempts to target the small GTPases directly have resulted in them being classed as "undruggable". The GTP-dependent signaling of these proteins is controlled by their regulators; guanine nucleotide exchange factors (GEFs), GTPase activating proteins (GAPs), and in the Rho and Rab subfamilies, guanine nucleotide dissociation inhibitors (GDIs). This review covers the recent small molecule and biologics strategies to target the small GTPases through their regulators. It seeks to critically re-evaluate recent chemical biology practice, such as the presence of PAINs motifs and the cell-based readout using compounds that are weakly potent or of unknown specificity. It highlights the vast scope of potential approaches for targeting the small GTPases in the future through their regulatory proteins.
Asunto(s)
Proteínas de Unión al GTP Monoméricas/metabolismo , Bibliotecas de Moléculas Pequeñas/química , Sitios de Unión , Evaluación Preclínica de Medicamentos , Humanos , Simulación de Dinámica Molecular , Proteínas de Unión al GTP Monoméricas/antagonistas & inhibidores , Proteínas de Unión al GTP Monoméricas/clasificación , Péptidos/química , Péptidos/metabolismo , Filogenia , Unión Proteica , Bibliotecas de Moléculas Pequeñas/metabolismo , Relación Estructura-ActividadRESUMEN
Parkinson's disease (PD) is a neurodegenerative disorder characterized by dopaminergic neuron loss. At present, there are no drugs that stop the progression of PD. As with other multifactorial genetic disorders, genome-wide association studies (GWASs) found multiple risk loci for PD, although their clinical significance remains uncertain. Here, we report the identification of candidate drugs for PD by a method using GWAS data and in silico databases. We identified 57 Food and Drug Administration-approved drug families as candidate neuroprotective drugs for PD. Among them, dabrafenib, which is known as a B-Raf kinase inhibitor and is approved for the treatment of malignant melanoma, showed remarkable cytoprotective effects in neurotoxin-treated SH-SY5Y cells and mice. Dabrafenib was found to inhibit apoptosis, and to enhance the phosphorylation of extracellular signal-regulated kinase (ERK), and inhibit the phosphorylation of c-Jun NH2-terminal kinase. Dabrafenib targets B-Raf, and we confirmed a protein-protein interaction between B-Raf and Rit2, which is coded by RIT2, a PD risk gene in Asians and Caucasians. In RIT2-knockout cells, the phosphorylation of ERK was reduced, and dabrafenib treatment improved the ERK phosphorylation. These data indicated that dabrafenib exerts protective effects against neurotoxicity associated with PD. By using animal model, we confirmed the effectiveness of this in silico screening method. Furthermore, our results suggest that this in silico drug screening system is useful in not only neurodegenerative diseases but also other common diseases such as diabetes mellitus and hypertension.
Asunto(s)
Imidazoles/administración & dosificación , Proteínas de Unión al GTP Monoméricas/genética , Fármacos Neuroprotectores/administración & dosificación , Oximas/administración & dosificación , Enfermedad de Parkinson/tratamiento farmacológico , Proteínas Proto-Oncogénicas B-raf/genética , Animales , Antineoplásicos/administración & dosificación , Apoptosis/efectos de los fármacos , Simulación por Computador , Citoprotección/efectos de los fármacos , Bases de Datos de Compuestos Químicos , Neuronas Dopaminérgicas/efectos de los fármacos , Neuronas Dopaminérgicas/patología , Aprobación de Drogas , Evaluación Preclínica de Medicamentos/métodos , Estudio de Asociación del Genoma Completo , Humanos , Proteínas Quinasas JNK Activadas por Mitógenos/genética , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Melanoma/tratamiento farmacológico , Ratones , Proteínas de Unión al GTP Monoméricas/antagonistas & inhibidores , Enfermedad de Parkinson/genética , Enfermedad de Parkinson/patología , Fosforilación/efectos de los fármacos , Mapas de Interacción de Proteínas , Inhibidores de Proteínas Quinasas/administración & dosificación , Proteínas Proto-Oncogénicas B-raf/antagonistas & inhibidoresRESUMEN
A previous study indicated that Rheb1 is required for mammalian target of TOR complex 1 (mTORC1) signaling in the brain. However, the function of Rheb1 in the heart is still elusive. In the present study, we deleted Rheb1 specifically in cardiomyocytes and found that reduced Rheb1 levels conferred cardioprotection against pathologic remodeling in myocardial infarction (MI) and pressure overload (transverse aortic constriction) mouse models. Cardiomyocyte apoptosis was reduced and mTORC1 activity was suppressed in cardiomyocyte Rheb1-deletion mice, suggesting that Rheb1 regulates mTORC1 activation in myocardium. Furthermore, we demonstrated that astragaloside IV (As-IV) could inhibit mTORC1, and As-IV treatment displayed similar protection against MI and transverse aortic constriction as Rheb1 genetic inhibition. This study indicates that Rheb1 is essential for mTORC1 activation in cardiomyocytes and suggests that targeting Rheb1-mTORC1 signaling, such as by As-IV treatment, may be an effective therapeutic method for treating patients with adverse cardiac remodeling after MI and hypertrophy.
Asunto(s)
Proteínas de Unión al GTP Monoméricas/antagonistas & inhibidores , Complejos Multiproteicos/metabolismo , Infarto del Miocardio/fisiopatología , Neuropéptidos/antagonistas & inhibidores , Serina-Treonina Quinasas TOR/metabolismo , Remodelación Ventricular/fisiología , Animales , Apoptosis/fisiología , Cardiomegalia/prevención & control , Cardiotónicos/farmacología , Cardiotónicos/uso terapéutico , Células Cultivadas , Evaluación Preclínica de Medicamentos/métodos , Eliminación de Gen , Diana Mecanicista del Complejo 1 de la Rapamicina , Ratones , Ratones Endogámicos C57BL , Proteínas de Unión al GTP Monoméricas/genética , Proteínas de Unión al GTP Monoméricas/fisiología , Infarto del Miocardio/metabolismo , Infarto del Miocardio/prevención & control , Miocitos Cardíacos/metabolismo , Miocitos Cardíacos/patología , Neuropéptidos/genética , Neuropéptidos/fisiología , Proteína Homóloga de Ras Enriquecida en el Cerebro , Saponinas/farmacología , Saponinas/uso terapéutico , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Triterpenos/farmacología , Triterpenos/uso terapéutico , Remodelación Ventricular/efectos de los fármacosRESUMEN
Macrophage infiltration into adipose tissue is associated with obesity and the crosstalk between adipocytes and infiltrated macrophages has been investigated as an important pathological phenomenon during adipose tissue inflammation. Here, we sought to identify adipocyte mRNAs that are regulated by interaction with infiltrated macrophages in vivo. An anti-inflammatory vitamin, vitamin B6, suppressed macrophage infiltration into white adipose tissue and altered mRNA expression. We identified >3500 genes whose expression is significantly altered during the development of obesity in db/db mice, and compared them to the adipose tissue mRNA expression profile of mice supplemented with vitamin B6. We identified PTX3 and MMP3 as candidate genes regulated by macrophage infiltration. PTX3 and MMP3 mRNA expression in 3T3-L1 adipocytes was up-regulated by activated RAW264.7 cells and these mRNA levels were positively correlated with macrophage number in adipose tissue in vivo. Next, we screened adipose genes down-regulated by the interaction with macrophages, and isolated RASSF6 (Ras association domain family 6). RASSF6 mRNA in adipocytes was decreased by culture medium conditioned by activated RAW264.7 cells, and RASSF6 mRNA level was negatively correlated with macrophage number in adipose tissue, suggesting that adipocyte RASSF6 mRNA expression is down-regulated by infiltrated macrophages in vivo. Finally, this study also showed that decreased RASSF6 expression up-regulates mRNA expression of several genes, such as CD44 and high mobility group protein HMGA2. These data provide novel insights into the biological significance of interactions between adipocytes and macrophages in adipose tissue during the development of obesity.
Asunto(s)
Adipocitos/metabolismo , Tejido Adiposo Blanco/metabolismo , Macrófagos/metabolismo , Proteínas de Unión al GTP Monoméricas/metabolismo , Obesidad/metabolismo , ARN Mensajero/metabolismo , Proteínas Supresoras de Tumor/metabolismo , Adipocitos/efectos de los fármacos , Adipocitos/patología , Tejido Adiposo Blanco/efectos de los fármacos , Tejido Adiposo Blanco/patología , Animales , Proteína C-Reactiva/genética , Proteína C-Reactiva/metabolismo , Comunicación Celular/efectos de los fármacos , Línea Celular , Movimiento Celular/efectos de los fármacos , Medios de Cultivo Condicionados/farmacología , Perfilación de la Expresión Génica , Regulación de la Expresión Génica/efectos de los fármacos , Proteína HMGA2/genética , Proteína HMGA2/metabolismo , Receptores de Hialuranos/genética , Receptores de Hialuranos/metabolismo , Macrófagos/efectos de los fármacos , Macrófagos/patología , Masculino , Metaloproteinasa 3 de la Matriz/genética , Metaloproteinasa 3 de la Matriz/metabolismo , Ratones , Ratones Transgénicos , Proteínas de Unión al GTP Monoméricas/antagonistas & inhibidores , Proteínas de Unión al GTP Monoméricas/genética , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/metabolismo , Obesidad/genética , Obesidad/patología , ARN Mensajero/genética , Transducción de Señal/efectos de los fármacos , Proteínas Supresoras de Tumor/antagonistas & inhibidores , Proteínas Supresoras de Tumor/genética , Vitamina B 6/farmacologíaRESUMEN
Mulberry, the fruit of Morus alba, is commonly used in Chinese medicines because of its many pharmacologic effects. Mulberry leaves contain many phenolic antioxidants that can reduce cardiovascular disease. Atherosclerosis involves proliferation and migration of vascular smooth muscle cell (VSMC). Thus, we investigated the mechanisms by which mulberry leaf extract (MLE) might inhibit migration of VSMC. MLE was rich in polyphenols (44.82%), including gallic acid, protocatechuic acid, catechin, gallocatechin gallate, caffeic acid, epicatechin, rutin, and quercetin. MLE could inhibit the migration of A7r5 cells in a dose- and time-dependent manner. MLE also inhibited the activities of matrix metalloproteinases (MMPs) MMP-2 and MMP-9, protein expressions, and phosphorylation of FAK and Akt, and protein expressions of small guanosine triphosphatases (GTPases: c-Raf, Ras, Rac1, Cdc42, and RhoA) in a dose-dependent manner. NF-kappaB expression was also inhibited by MLE. MLE could effectively inhibit the migration of VSMC by blocking small GTPase and Akt/NF-kappaB signals.
Asunto(s)
Movimiento Celular/efectos de los fármacos , Morus/química , Músculo Liso Vascular/citología , Extractos Vegetales/farmacología , Hojas de la Planta/química , Transducción de Señal/efectos de los fármacos , Animales , Línea Celular , Inhibidores Enzimáticos/farmacología , Flavonoides/análisis , Inhibidores de la Metaloproteinasa de la Matriz , Proteínas de Unión al GTP Monoméricas/antagonistas & inhibidores , Proteínas de Unión al GTP Monoméricas/metabolismo , FN-kappa B/antagonistas & inhibidores , FN-kappa B/metabolismo , Fenoles/análisis , Fosforilación/efectos de los fármacos , Extractos Vegetales/química , Polifenoles , Proteínas Proto-Oncogénicas c-akt/antagonistas & inhibidores , Proteínas Proto-Oncogénicas c-akt/metabolismo , RatasRESUMEN
Guanine nucleotide exchange factors (GEFs) are essential regulators of the spatiotemporal conditions of small GTP-binding protein (SMG) activation. Their cellular activities combine the biochemical stimulation of GDP/GTP exchange, which leads to the active conformation of the SMG, to the detection of upstream signals and, in some cases, interaction with downstream effectors. Inhibition of GEF activities by small molecules has become recently a very active field, both for understanding biology with the tools of chemistry and because GEFs are emerging as therapeutic targets. The natural compound brefeldin A (BFA) was the first inhibitor of a GEF to be characterized, and several inhibitors of SMG activation have since been discovered using a variety of screening methods. An essential step toward their use in basic research or as leads in therapeutics is the characterization of their mechanism of inhibition. GEFs function according to a multistep mechanism, involving transient ternary (nucleotide-bound) and binary (nucleotide-free) intermediates. This mechanism thereby offers many opportunities for blockage, but a thorough analysis is necessary to define the inhibition mechanism and the steps of the reaction that are affected by the inhibitor. Here, based on the case study of how BFA inhibits the activation of Arf activation by Sec7 domains, we describe a flowchart of assays to decipher the mechanism of inhibitors of the activation of SMGs by their GEFs.